Tandem Diabetes Care Inc (TNDM) EVP David B. Berger Sells 11,493 Shares of Stock

Share on StockTwits

Tandem Diabetes Care Inc (NASDAQ:TNDM) EVP David B. Berger sold 11,493 shares of the business’s stock in a transaction dated Thursday, December 6th. The shares were sold at an average price of $34.54, for a total transaction of $396,968.22. Following the completion of the transaction, the executive vice president now owns 11,765 shares in the company, valued at $406,363.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ TNDM traded down $1.63 during trading on Friday, reaching $33.49. The company had a trading volume of 1,209,840 shares, compared to its average volume of 1,383,724. Tandem Diabetes Care Inc has a 52 week low of $2.14 and a 52 week high of $52.55. The company has a market cap of $2.01 billion, a PE ratio of -2.60 and a beta of 0.52.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Thursday, November 1st. The medical device company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.28). Tandem Diabetes Care had a negative return on equity of 204.32% and a negative net margin of 93.07%. The company had revenue of $46.30 million during the quarter, compared to the consensus estimate of $42.71 million. During the same period in the prior year, the firm posted ($3.09) earnings per share. The company’s revenue was up 71.5% on a year-over-year basis. As a group, research analysts expect that Tandem Diabetes Care Inc will post -1.31 earnings per share for the current year.

A number of research firms have commented on TNDM. BidaskClub upgraded shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 23rd. Lake Street Capital boosted their price target on shares of Tandem Diabetes Care from $35.00 to $65.00 and gave the company a “buy” rating in a research report on Monday, August 20th. Dougherty & Co began coverage on shares of Tandem Diabetes Care in a research report on Friday, August 24th. They issued a “buy” rating and a $45.00 price target on the stock. Berenberg Bank began coverage on shares of Tandem Diabetes Care in a research report on Thursday, August 30th. They issued a “buy” rating and a $50.00 price target on the stock. Finally, Oppenheimer set a $57.00 price target on shares of Tandem Diabetes Care and gave the company a “buy” rating in a research report on Friday, November 2nd. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $44.75.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Cortina Asset Management LLC bought a new position in shares of Tandem Diabetes Care in the second quarter worth about $6,861,000. Rhumbline Advisers bought a new position in shares of Tandem Diabetes Care in the second quarter worth about $943,000. Royal Bank of Canada raised its stake in shares of Tandem Diabetes Care by 2,375,000.0% in the first quarter. Royal Bank of Canada now owns 47,502 shares of the medical device company’s stock worth $236,000 after acquiring an additional 47,500 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Tandem Diabetes Care in the third quarter worth about $203,000. Finally, Voya Investment Management LLC bought a new stake in shares of Tandem Diabetes Care during the second quarter worth approximately $386,000. 71.60% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/12/08/tandem-diabetes-care-inc-tndm-evp-david-b-berger-sells-11493-shares-of-stock/3064970.html.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Story: Put Option

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.